Provided by Tiger Fintech (Singapore) Pte. Ltd.

Altimmune, Inc.

4.80
+0.25005.49%
Volume:1.62M
Turnover:7.66M
Market Cap:369.67M
PE:-3.59
High:4.86
Open:4.43
Low:4.37
Close:4.55
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Goldman Sachs, Pfizer, Best Buy

Reuters
·
14 Apr

BUZZ-Obesity drugmakers rise after Pfizer ends development of weight-loss pill

Reuters
·
14 Apr

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

GlobeNewswire
·
14 Apr

Altimmune's US$42m Market Cap Fall Books Insider Losses

Simply Wall St.
·
10 Apr

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

GlobeNewswire
·
08 Apr

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
08 Apr

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets

Dow Jones
·
02 Apr

Altcoin Listings Spark Buzz in Crypto World

CoinMarketCap
·
27 Mar

Coinbase to List ALT, PENDLE, and L3

Blockbeats
·
27 Mar

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

Business Wire
·
24 Mar

ALT Soars Over 18% Briefly Before Falling Back, Currently Trading at $0.038

Blockbeats
·
21 Mar

Coinbase Adds ALT, PENDLE, and L3 to Asset Listing Roadmap

Blockbeats
·
21 Mar

Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Dow Jones
·
20 Mar

Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Mar

Altimmune call volume above normal and directionally bullish

TIPRANKS
·
15 Mar

Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets

Dow Jones
·
14 Mar

Altimmune Shares up 4.5% on Plans to Test Obesity Drug for Alcohol Use Disorder, Other Conditions

THOMSON REUTERS
·
14 Mar

BRIEF-Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025

Reuters
·
14 Mar

BUZZ-Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions

Reuters
·
14 Mar